Nuevos fármacos en el tratamiento de los linfomas cutáneos de células T New drugs in the therapy of T-cell cutaneous lymphoma

Summary There is currently no curative treatment of cutaneous lymphomas in advanced stages. Historically these patients have been treated with chemotherapy regimens used in systemic lymphomas usually very toxic and with limited benefits. With the growing knowledge about the pathogenesis of cutaneous lymphomas it has been able to identify therapeutic targets and to develop new molecules that currently are being tested with promising results. This is the case of histone deacetylase inhibitors (IHDAC) and the new monoclonal antibodies, among others. In the same way it has been found that useful drugs in other tumors, such as gemcitabine, bortezomib and liposomal doxorubicin are also active in the LCP-T, at least in preliminary studies. In the last years, new drugs and therapeutic strategies are being added to our arsenal with the purpose of changing the natural history of this disease. In this article we review the therapeutic advances in this field.